• September 25, 2021
    • Loading stock data...
  • ‘Another level’: Race on to get over-the-counter cannabis meds to pharmacies


    ASX-listed cannabis companies are racing to get low-dose medicinal pot products onto shelves, with hopes they will be available through pharmacies by the end of next year.

    In February, the country’s medicines regulator – the Therapeutic Goods Administration (TGA) – agreed to change the classification for certain products containing small amounts of cannabidiol (CBD), an active ingredient in the cannabis plant that does not get the user high but is used in therapeutic products.

    Under the new rules, cannabis medicines in this category are classified as “schedule 3” medicines and can be sold in pharmacies without the need for a prescription. However, no Australian products currently fit the criteria for an over-the-counter medicine, meaning drug developers must set up clinical trials for new products and show that they work before anything can be sold to consumers.

    Read full article here: https://www.smh.com.au/business/companies/another-level-race-on-to-get-over-the-counter-cannabis-meds-to-pharmacies-20210907-p58pex.html?mc_cid=4723afa565&mc_eid=b20cd943c2


    About Author

    Comments are closed.